Parenteral formulations of treprostinil
US-9713599-B2 · Jul 25, 2017 · US
Inhalation formulations of treprostinil
US10695308B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10695308-B2 |
| Application number | US-201816131248-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 14, 2018 |
| Priority date | Dec 16, 2003 |
| Publication date | Jun 30, 2020 |
| Grant date | Jun 30, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
First claim
Opening claim text (preview).
I claim: 1. A method of treating a human patient suffering from pulmonary hypertension, comprising: providing an infusion solution comprising 0.1 to 5% w/v of treprostinil or a pharmaceutically acceptable salt or ester thereof, and intravenously administering the infusion solution to the human patient at a rate of from 0.625 to 50 ng/kg/min, wherein the infusion solution is sterile and isotonic with blood. 2. The method of claim 1 , wherein the infusion solution is administered at a rate of 0.1 ml/min/kg. 3. The method of claim 1 , wherein the rate of administration is from 10 to 15 ng/kg/min.
Assignees
Inventors
Classifications
- A61K31/5575Primary
having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha · CPC title
substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone · CPC title
Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) · CPC title
having one or two double bonds, e.g. oleic, linoleic acids · CPC title
having two or more hydroxy groups, e.g. gluconic acid · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10695308B2 cover?
- The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The inventio…
- Who is the assignee on this patent?
- United Therapeutics Corp
- What technology area does this patent fall under?
- Primary CPC classification A61K31/5575. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).